- Raised $10.3M funding round led by Bill & Melinda Gates Foundation, Nov 2024
- Raised $7.3M funding round, Aug 2008
- Raised $12M funding round, Nov 2006
About
Interna Therapeutics is an innovative biotechnology company that developed a transformational delivery technology for macromolecules. The pioneering technology, named Molecular Nano-Motors (MNMs), is based on a novel mechanism that leverages membrane electrical forces, facilitating entry of charged molecules into cells. With this technology new treatment options become available for a wide range of diseases using difficult to deliver molecules such as oligonucleotide-based drugs (siRNA, ASO). Equipped with full-capacity research facilities and working with leading research organizations, the team of seasoned scientists has demonstrated the therapeutic potential of MNM technology in numerous preclinical studies, with a Phase I study of a COVID-19 drug that began in September 2024. Interna’s innovative spirit and scientific excellence has been recognized by key opinion leaders in the pharma industry and by non-governmental organizations.
Funding history · 4 rounds · $57.5M total
Q&A
- What is Interna Therapeutics' primary focus?
- Interna Therapeutics is an innovative biotechnology company focused on drug delivery via electrical nano motors, specifically developing Molecular Nano-Motors (MNMs) for macromolecule delivery.
- When was Interna Therapeutics founded?
- Interna Therapeutics was founded in October 1996.
- How many employees does Interna Therapeutics have?
- Interna Therapeutics has 11-50 employees.
- What is the total amount of funding Interna Therapeutics has raised to date?
- Interna Therapeutics has raised a total of $57,550,000 USD.
- When was Interna Therapeutics' most recent funding round, and who were the lead investors?
- Interna Therapeutics' most recent funding round occurred in November 2024, with the Bill & Melinda Gates Foundation as a lead investor.
- What is the status of Interna Therapeutics' COVID-19 drug development?
- A Phase I study for Interna Therapeutics' COVID-19 drug began in September 2024.
- What is Interna Therapeutics' core technology?
- Interna Therapeutics' core technology is Molecular Nano-Motors (MNMs), which leverage membrane electrical forces to facilitate the entry of charged molecules into cells for drug delivery.
- What types of diseases does Interna Therapeutics' technology aim to address?
- Interna Therapeutics' technology aims to provide new treatment options for a wide range of diseases by delivering difficult-to-deliver molecules such as oligonucleotide-based drugs (siRNA, ASO).
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | interna.bio |
|---|---|
| linkedin.com/company/1833144 | |
| YouTube | youtube.com/user/Aposense |
Identifiers & details
| Former names | NST |
|---|---|
| Founded | 1996-10 |
| Employees (exact) | 19 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | interna.bio |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|